<DOC>
	<DOCNO>NCT00309088</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety steroid non-resistant MG patient double blind , placebo control study .</brief_summary>
	<brief_title>FK506 Phase 3 Study : Study Steroid Non-resistant Myasthenia Gravis ( MG ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Clinically diagnose myasthenia gravis Those whose MG symptom wellcontrolled treatment prednisone Steroid nonrefractory Myasthenia Gravis : ≧20mg ≦40mg / alternate day steroid dose required maintain Those thymoma history thymoma ( Masaoka stage III IV ) Patients receive steroid pulse therapy , plasma exchange therapy , globulin therapy radiation therapy within 12 week prior initiation test drug Patients start immunosuppressant therapy increase dose immunosuppressant within 12 week prior initiation test drug . Patients undergone thymectomy within 24 week prior initiation test drug . Pancreatitis diabetes Serum creatinine≦1.5mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Myasthenia Gravis</keyword>
</DOC>